Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
With upcoming news flow from AVA6000 and indeed AVA3996/ AVA2727D a complete re-rating of the therapeutic business is very likely and hence the current share price is a gift and the company come Q2 will be a very exciting therapeutic company with an incredible news flow ahead.
Worth reminding us that GenScript ProBio Signed CDMO Supply Agreement And Formed Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta venture .GenScript also acquired more equity as well.At what valuation ? Ref Avacta's nil cost 20% holding.
Would be interesting to know at what valuation was their recent stake acquired at?
Read across to Avacta's nil cost holding in Affyxell !
Precision medicine was the talk of the town, especially on day three of the 2024 JPM conference.
It was very clear that precision medicine was one of the buzzwords at the 2024 JPM convention, along with artificial intelligence (AI).
AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.
There was also an heightened interest in AI and precision medicine directly, with a lot of interest AI-based soluble TCR therapeutics platform, which is generating precision medicines for oncology and auto-immune diseases,”.
AI in drug discovery is set to reach $5 billion in the next four years, as the technology aims to develop drugs quicker and cheaper.
From Vox Markets
https://www.voxmarkets.co.uk/articles/vox-markets-fund-manager-series-gervais-williams-of-premier-miton-d6fb11c
The timing of this appointment is the clearest sign that the Therapeutic business carries top priority for Avacta and that AVA6000 will soon make more headlines and valuation of global Precision is going north pre ACCR.
Also worth reminding ourselves head therapeutics lives in the States!
Two new initial public offerings (IPO) are set to go ahead in the USA, raising hopes of a thaw in what has been a long winter for biotech companies going public.
Kyverna Therapeutics has filed paperwork with the US financial regulator for its IPO, which is targeting a fundraise of around $100 million.
Another Californian firm, Alto Neuroscience, has filed for an IPO of an undisclosed size.
One should remind yourself of what happened back in September:
"Avacta shares surged on Tuesday after CEO Dr Alastair Smith said he believed Avacta are ‘on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.”
UK biotech company Avacta Group has announced positive results from the latest cohort in its clinical trial of AVA6000, the company’s targeted chemotherapy drug".
Then remind yourself that in Avacta's case, "silence is golden", as the company has not published any negative test results.
Highly ranked directors have joined the company, the Therapeutic division will attract a tremendous amount of attention before and at the upcoming ACCR conference.
Investors taking advantage of current share price, will look very clever very soon!